Skip to content
Home / Companies / MDGL MDG
MADRIGAL PHARMACEUTICALS, INC. (MDGL) XNAS PHARMACEUTICAL PREPARATIONS Net insider selling (90d)
Latest MDGL Insider Trades
About MADRIGAL PHARMACEUTICALS, INC. (MDGL) Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Headquarters WEST CONSHOHOCKEN, PA
Employees 915
Listed 2007
Exchange XNAS https://www.madrigalpharma.com SEC filings for MDGL on EDGAR
90-Day SEC Filing Activity Form 4 transaction type Transactions Shares Total value Open-market sale 11 3,164 $1.71M Grant or award 16 12,570 Option exercise 2 100,000
MDGL Insider Transactions (Form 4) 197 58 Form 4 filings on record, the earliest from Nov 5, 2024, newest first. Filing history page 2 of 2.
Date Insider Transaction Security Shares Price Value Nov 13, 2025 RL Richard S. Levy - Director Open-market sale Common Stock 645
Recent MDGL Form 8-K Filings 5
Recent MDGL Form 144 Notices of Proposed Sale 3 A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
Filed Filer Relationship Shares Market value Notice Aug 20, 2026 Shannon Kelley Officer 664 $337K View on EDGAR Jul 20, 2026 - -
MDGL Insider Trading - FAQ
What is the latest insider trade for MDGL? MADRIGAL PHARMACEUTICALS, INC. (MDGL) had 9 insider filings in the last 90 days, with the most recent on 2026-08-20. The full record for MDGL runs to 58 Form 4 filings, the earliest from 2024-11-05. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
How many insiders are buying MDGL stock? No insider purchases of MDGL were filed in the last 90 days. 26 purchases are on record for this company.
How many insiders are selling MDGL stock? 11 insider sales of MDGL were filed in the last 90 days, totaling $1.71M.
Where can I see MDGL SEC filings (Form 4, 10-K, 10-Q, 8-K)? This page tracks MDGL Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
How can I follow MDGL insider buys? Create a free InsiderAlpha account and press Watch on this page to add MDGL to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
More Health Care Companies with Insider Activity Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Related Companies - Recent Insider Activity What is SEC Form 4? The filing insiders must submit within two business days of a trade, and how to read its transaction codes. Track MDGL insider activity as it files Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
Sign up free $76K
Market cap $12.33B
P/E ratio -
Dividend yield -
Average volume 357.1K
52 week high $615.00
52 week low $393.61
Today's high $542.16
Today's low $528.29
Open $539.38
Volume 268.7K
Previous close $543.69
Shares outstanding 23.10M Market cap
$12.33B
915 employees
MDGL Insider Sentiment - Last 90 Days Share of open-market insider dollar volume that was buying versus selling, from SEC Form 4 filings.
0% Buying 100% Selling
0 insider purchases totaling $0 against 11 sales totaling $1.71M.
Most-Active MDGL Insiders - Last 90 Days 10 Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
Nov 13, 2025 RL Richard S. Levy - Director Open-market sale Common Stock 835 $518.53 $433K
Nov 13, 2025 RL Richard S. Levy - Director Open-market sale Common Stock 1,355 $519.67 $704K
Nov 13, 2025 RL Richard S. Levy - Director Open-market sale Common Stock 308 $520.68 $160K
Nov 13, 2025 RL Richard S. Levy - Director Open-market sale Common Stock 1,094 $521.79 $571K
Nov 13, 2025 RL Richard S. Levy - Director Open-market sale Common Stock 1,434 $522.70 $750K
Nov 13, 2025 RL Richard S. Levy - Director Open-market sale Common Stock 811 $523.66 $425K
Nov 13, 2025 RL Richard S. Levy - Director Open-market sale Common Stock 153 $524.49 $80K
Nov 13, 2025 RL Richard S. Levy - Director Open-market sale Common Stock 120 $526.68 $63K
Nov 13, 2025 RL Richard S. Levy - Director Open-market sale Common Stock 200 $527.85 $106K
Nov 13, 2025 RL Richard S. Levy - Director Open-market sale Common Stock 440 $528.60 $233K
Nov 13, 2025 RL Richard S. Levy - Director Open-market sale Common Stock 40 $530.21 $21K
Nov 13, 2025 RL Richard S. Levy - Director Option exercise Stock Option (Right to Buy) 2,500 $0.00 -
Nov 13, 2025 RL Richard S. Levy - Director Option exercise Stock Option (Right to Buy) 6,000 $0.00 -
Nov 13, 2025 RL Richard S. Levy - Director Option exercise Common Stock 2,500 $7.36 $18K
Nov 13, 2025 RL Richard S. Levy - Director Option exercise Common Stock 6,000 $16.46 $99K
Nov 13, 2025 RL Richard S. Levy - Director Open-market sale Common Stock 146 $514.67 $75K
Nov 13, 2025 RL Richard S. Levy - Director Open-market sale Common Stock 919 $515.64 $474K
Nov 5, 2025 KB Kenneth Bate - Director Open-market sale Common Stock 3,259 $481.13 $1.57M
Nov 5, 2025 KB Kenneth Bate - Director Open-market sale Common Stock 1,284 $482.41 $619K
Nov 5, 2025 KB Kenneth Bate - Director Open-market sale Common Stock 2,069 $483.41 $1.00M
Nov 5, 2025 KB Kenneth Bate - Director Open-market sale Common Stock 1,931 $484.78 $936K
Nov 5, 2025 KB Kenneth Bate - Director Open-market sale Common Stock 1,008 $485.54 $489K
Nov 5, 2025 KB Kenneth Bate - Director Open-market sale Common Stock 827 $486.73 $403K
Nov 5, 2025 KB Kenneth Bate - Director Open-market sale Common Stock 2,775 $487.49 $1.35M
Nov 5, 2025 KB Kenneth Bate - Director Open-market sale Common Stock 696 $489.09 $340K
Nov 5, 2025 KB Kenneth Bate - Director Open-market sale Common Stock 933 $489.95 $457K
Nov 5, 2025 KB Kenneth Bate - Director Open-market sale Common Stock 30 $490.98 $15K
Nov 5, 2025 KB Kenneth Bate - Director Option exercise Stock Option (Right to Buy) 5,470 $0.00 -
Nov 5, 2025 KB Kenneth Bate - Director Option exercise Stock Option (Right to Buy) 10,000 $0.00 -
Nov 5, 2025 KB Kenneth Bate - Director Option exercise Stock Option (Right to Buy) 1,105 $0.00 -
Nov 5, 2025 KB Kenneth Bate - Director Option exercise Common Stock 5,470 $9.45 $52K
Nov 5, 2025 KB Kenneth Bate - Director Option exercise Common Stock 10,000 $303.79 $3.04M
Nov 5, 2025 KB Kenneth Bate - Director Option exercise Common Stock 1,105 $280.04 $309K
Nov 5, 2025 KB Kenneth Bate - Director Open-market sale Common Stock 1,763 $480.24 $847K
Aug 15, 2025 KB Kenneth Bate - Director Option exercise Common Stock 10,000 $16.46 $165K
Aug 15, 2025 KB Kenneth Bate - Director Open-market sale Common Stock 2,317 $363.41 $842K
Aug 15, 2025 KB Kenneth Bate - Director Open-market sale Common Stock 2,516 $364.24 $916K
Aug 15, 2025 KB Kenneth Bate - Director Open-market sale Common Stock 2,567 $365.33 $938K
Aug 15, 2025 KB Kenneth Bate - Director Open-market sale Common Stock 600 $366.14 $220K
Aug 15, 2025 KB Kenneth Bate - Director Open-market sale Common Stock 1,104 $367.63 $406K
Aug 15, 2025 KB Kenneth Bate - Director Open-market sale Common Stock 896 $368.56 $330K
Aug 15, 2025 KB Kenneth Bate - Director Option exercise Stock Option (Right to Buy) 10,000 $0.00 -
Aug 13, 2025 PF Paul A. Friedman - Director Option exercise Common Stock 129,172 $9.45 $1.22M
Aug 13, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 1,600 $358.23 $573K
Aug 13, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 455 $359.31 $163K
Aug 13, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 3,153 $360.27 $1.14M
Aug 13, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 1,754 $361.13 $633K
Aug 13, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 1,439 $362.29 $521K
Aug 13, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 2,591 $363.08 $941K
Aug 13, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 3,529 $364.02 $1.28M
Aug 13, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 1,716 $365.19 $627K
Aug 13, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 3,152 $366.22 $1.15M
Aug 13, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 7,119 $367.31 $2.61M
Aug 13, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 6,788 $368.34 $2.50M
Aug 13, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 7,992 $369.44 $2.95M
Aug 13, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 7,877 $370.44 $2.92M
Aug 13, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 22,710 $371.53 $8.44M
Aug 13, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 28,976 $372.39 $10.79M
Aug 13, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 24,166 $373.35 $9.02M
Aug 13, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 4,155 $374.38 $1.56M
Aug 13, 2025 PF Paul A. Friedman - Director Option exercise Stock Option (Right to Buy) 129,172 $0.00 -
Aug 11, 2025 PF Paul A. Friedman - Director Option exercise Common Stock 3,203 $9.45 $30K
Aug 11, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 2,903 $350.19 $1.02M
Aug 11, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 300 $351.04 $105K
Aug 12, 2025 PF Paul A. Friedman - Director Option exercise Common Stock 43,605 $9.45 $412K
Aug 12, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 3,303 $350.93 $1.16M
Aug 12, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 3,202 $351.59 $1.13M
Aug 12, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 1,382 $352.61 $487K
Aug 12, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 4,768 $354.06 $1.69M
Aug 12, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 6,546 $355.00 $2.32M
Aug 12, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 5,244 $355.97 $1.87M
Aug 12, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 5,094 $356.94 $1.82M
Aug 12, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 8,434 $357.93 $3.02M
Aug 12, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 5,032 $358.83 $1.81M
Aug 12, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 600 $359.81 $216K
Aug 11, 2025 PF Paul A. Friedman - Director Option exercise Stock Option (Right to Buy) 3,203 $0.00 -
Aug 12, 2025 PF Paul A. Friedman - Director Option exercise Stock Option (Right to Buy) 43,605 $0.00 -
Aug 11, 2025 RT Rebecca Taub - Director Option exercise Common Stock 3,200 $9.45 $30K
Aug 11, 2025 RT Rebecca Taub - Director Open-market sale Common Stock 2,980 $350.18 $1.04M
Aug 11, 2025 RT Rebecca Taub - Director Open-market sale Common Stock 220 $351.02 $77K
Aug 12, 2025 RT Rebecca Taub - Director Option exercise Common Stock 43,263 $9.45 $409K
Aug 12, 2025 RT Rebecca Taub - Director Open-market sale Common Stock 3,580 $350.87 $1.26M
Aug 12, 2025 RT Rebecca Taub - Director Open-market sale Common Stock 2,870 $351.60 $1.01M
Aug 12, 2025 RT Rebecca Taub - Director Open-market sale Common Stock 1,175 $352.45 $414K
Aug 12, 2025 RT Rebecca Taub - Director Open-market sale Common Stock 4,587 $354.04 $1.62M
Aug 12, 2025 RT Rebecca Taub - Director Open-market sale Common Stock 6,479 $354.97 $2.30M
Aug 12, 2025 RT Rebecca Taub - Director Open-market sale Common Stock 5,752 $355.95 $2.05M
Aug 12, 2025 RT Rebecca Taub - Director Open-market sale Common Stock 4,864 $356.88 $1.74M
Aug 12, 2025 RT Rebecca Taub - Director Open-market sale Common Stock 6,715 $357.85 $2.40M
Aug 12, 2025 RT Rebecca Taub - Director Open-market sale Common Stock 6,541 $358.81 $2.35M
Aug 12, 2025 RT Rebecca Taub - Director Open-market sale Common Stock 700 $359.71 $252K
Aug 11, 2025 RT Rebecca Taub - Director Option exercise Stock Option (Right to Buy) 3,200 $0.00 -
Aug 12, 2025 RT Rebecca Taub - Director Option exercise Stock Option (Right to Buy) 43,263 $0.00 -
Aug 1, 2025 DB Daniel J. Brennan - Director Grant or award Stock Option (Right to Buy) 1,705 $0.00 -
Jul 18, 2025 PF Paul A. Friedman - Director Option exercise Common Stock 1,400 $9.45 $13K
Jul 18, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 1,400 $350.03 $490K
Jul 18, 2025 PF Paul A. Friedman - Director Option exercise Stock Option (Right to Buy) 1,400 $0.00 -
Jul 18, 2025 RT Rebecca Taub - Director Option exercise Common Stock 1,000 $9.45 $9K
Jul 18, 2025 RT Rebecca Taub - Director Open-market sale Common Stock 1,000 $350.01 $350K
Jul 18, 2025 RT Rebecca Taub - Director Option exercise Stock Option (Right to Buy) 1,000 $0.00 -
Jul 16, 2025 RT Rebecca Taub - Director Option exercise Common Stock 26,444 $9.45 $250K
Jul 16, 2025 RT Rebecca Taub - Director Open-market sale Common Stock 6,000 $350.19 $2.10M
Jul 16, 2025 RT Rebecca Taub - Director Open-market sale Common Stock 1,897 $351.37 $667K
Jul 16, 2025 RT Rebecca Taub - Director Open-market sale Common Stock 2,357 $352.64 $831K
Jul 16, 2025 RT Rebecca Taub - Director Open-market sale Common Stock 2,569 $353.82 $909K
Jul 16, 2025 RT Rebecca Taub - Director Open-market sale Common Stock 5,800 $354.61 $2.06M
Jul 16, 2025 RT Rebecca Taub - Director Open-market sale Common Stock 6,441 $355.61 $2.29M
Jul 16, 2025 RT Rebecca Taub - Director Open-market sale Common Stock 1,380 $356.52 $492K
Jul 17, 2025 RT Rebecca Taub - Director Option exercise Common Stock 2,657 $9.45 $25K
Jul 17, 2025 RT Rebecca Taub - Director Open-market sale Common Stock 2,057 $350.09 $720K
Jul 17, 2025 RT Rebecca Taub - Director Open-market sale Common Stock 600 $351.50 $211K
Jul 16, 2025 RT Rebecca Taub - Director Option exercise Stock Option (Right to Buy) 26,444 $0.00 -
Jul 17, 2025 RT Rebecca Taub - Director Option exercise Stock Option (Right to Buy) 2,657 $0.00 -
Jul 16, 2025 PF Paul A. Friedman - Director Option exercise Common Stock 26,176 $9.45 $247K
Jul 16, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 5,541 $350.17 $1.94M
Jul 16, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 2,371 $351.38 $833K
Jul 16, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 2,110 $352.67 $744K
Jul 16, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 2,319 $353.82 $821K
Jul 16, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 6,851 $354.65 $2.43M
Jul 16, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 5,784 $355.61 $2.06M
Jul 16, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 1,200 $356.62 $428K
Jul 17, 2025 PF Paul A. Friedman - Director Option exercise Common Stock 2,700 $9.45 $26K
Jul 17, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 2,000 $350.10 $700K
Jul 17, 2025 PF Paul A. Friedman - Director Open-market sale Common Stock 700 $351.57 $246K
Jul 16, 2025 PF Paul A. Friedman - Director Option exercise Stock Option (Right to Buy) 26,176 $0.00 -
Jul 17, 2025 PF Paul A. Friedman - Director Option exercise Stock Option (Right to Buy) 2,700 $0.00 -
Jun 20, 2025 PF Paul A. Friedman - Director Grant or award Stock Option (Right to Buy) 1,290 $0.00 -
Jun 20, 2025 KB Kenneth Bate - Director Grant or award Common Stock 715 $0.00 -
Jun 20, 2025 KB Kenneth Bate - Director Grant or award Stock Option (Right to Buy) 1,290 $0.00 -
Jun 20, 2025 JF Jacqualyn A. Fouse - Director Grant or award Stock Option (Right to Buy) 366 $0.00 -
Jun 20, 2025 JD James M. Daly - Director Grant or award Common Stock 715 $0.00 -
Jun 20, 2025 JD James M. Daly - Director Grant or award Stock Option (Right to Buy) 1,290 $0.00 -
Jun 20, 2025 RL Richard S. Levy - Director Grant or award Common Stock 715 $0.00 -
Jun 20, 2025 RL Richard S. Levy - Director Grant or award Stock Option (Right to Buy) 1,290 $0.00 -
May 15, 2025 DS David Soergel - Officer Grant or award Common Stock 7,545 $0.00 -
May 15, 2025 DS David Soergel - Officer Grant or award Stock Option (Right to Buy) 12,839 $0.00 -
Apr 10, 2025 RL Richard S. Levy - Director Option exercise Common Stock 9,470 $65.06 $616K
Apr 10, 2025 RL Richard S. Levy - Director Option exercise Stock Option (Right to Buy) 9,470 $0.00 -
Dec 3, 2024 FC Fred B. Craves - Director Open-market sale Common Stock 3,080 $315.21 $971K
Dec 3, 2024 FC Fred B. Craves - Director Open-market sale Common Stock 520 $315.90 $164K
Nov 25, 2024 FC Fred B. Craves - Director Open-market sale Common Stock 2,200 $350.08 $770K
Nov 25, 2024 FC Fred B. Craves - Director Open-market sale Common Stock 1,200 $350.71 $421K
Nov 21, 2024 CH Carole Huntsman - Officer Open-market sale Common Stock 688 $316.92 $218K
Nov 7, 2024 RL Richard S. Levy Option exercise Stock Option (Right to Buy) 5,000 $0.00 -
Nov 1, 2024 RL Richard S. Levy Option exercise Stock Option (Right to Buy) 5,000 $0.00 -
$MGTX
MeiraGTx Holdings plc
$IONS
IONIS PHARMACEUTICALS INC
